Enhanced SOX2 expression was reported to confer tamoxifen resistance in the MCF-7 cell line and SOX2 expression is also higher in breast cancer tissue taken from patients after endocrine therapy failure [45], suggesting that the development of tamoxifen resistance is associated with activation of the pathway leading to SOX2-expression [45]. This evidence concerns the gene SOX2 and breast cancer.